

FCRL6 Polyclonal Antibody

Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP56101

Product Information

Application	IHC-P, IHC-F, IF, ICC, E
Primary Accession	Q6DN72
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Calculated MW	47748

Additional Information

Gene ID	343413
Other Names	Fc receptor-like protein 6, FcR-like protein 6, FCRL6, Fc receptor homolog 6, FcRH6, IFGP6, FCRL6, FCRH6
Dilution	IHC-P=1:100-500,IHC-F=1:100-500,ICC=1:100-500,IF=1:100-500,ELISA=1:5000-10000
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Protein Information

Name	FCRL6
Synonyms	FCRH6
Function	Acts as a MHC class II receptor (PubMed: 20519654). When stimulated on its own, does not play a role in cytokine production or the release of cytotoxic granules by NK cells and cytotoxic CD8(+) T cells (PubMed: 17213291 , PubMed: 18991291). Does not act as an Fc receptor (PubMed: 18991291).
Cellular Location	Cell membrane; Single-pass type I membrane protein
Tissue Location	Expressed by cytolytic cells including NK cells, effector and effector-memory CD8(+) T-cells, and a subset of NKT cells (at protein level) (PubMed:17213291, PubMed:18991291, PubMed:20933011) Also expressed in gamma delta T cells and in a rare subset of effector CD4(+) T-cells (at protein level) (PubMed:18991291). Expressed in spleen, skin, peripheral blood leukocytes, liver, lung, bone marrow, small intestine and placenta (PubMed:20933011). Expression among T- cells is greatly expanded in HIV-1 infected individuals, and includes not only effector and effector-memory CD8(+) T-cells but also

populations of CD4(+) T-cells (PubMed:17213291, PubMed:20933011)
Expression among CD8(+) T-cells and NK cells is expanded in individuals with chronic lymphocytic leukemia (CLL) but is reduced in PBMCs from patients with acute (AML), chronic myeloid leukemia (CML) and non- Hodgkin's lymphoma (PubMed:18991291, PubMed:20933011). Expression is higher in PBMCs and/or CD3(+) cells of patients with autoimmune diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and idiopathic thrombocytopenia purpura (ITP) (PubMed:20933011). In contrast, expression in CD3(+) cells from patients with lupus anticoagulans (LA) is higher (PubMed:20933011)

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.